Prognose

Das durchschnittliche Kursziel der Analysten beträgt +158,31€(+11,09%). Der Median liegt bei +158,31€(+11,09%).

Kaufen	21
Halten	1
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	5 / 18
Levermann-Strategie	-2 / 13

News

Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") are pleased to announce the successful completion of the previously announced plan of arrangement (the "Arrangement") under the Business Corporations Act (Ontario) pursuant to which Cerrado has acquired all of the issued and outstanding common shares of Ascendant ("Ascendant Shares") that it did not already own. The Arrangement was carried out pursuant to the terms of the arrangement agreement between Ascendant and Cerrado dated February 3, 2025, as amended, (the "Arrangement Agreement") and became effective on May 16, 2025, resulting in Ascendant becoming a wholly owned subsidiary of Cerrado.» Mehr auf accessnewswire.com
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") are pleased to announce the successful completion of the previously announced plan of arrangement (the "Arrangement") under the Business Corporations Act (Ontario) pursuant to which Cerrado has acquired all of the issued and outstanding common shares of Ascendant ("Ascendant Shares") that it did not already own. The Arrangement was carried out pursuant to the terms of the arrangement agreement between Ascendant and Cerrado dated February 3, 2025, as amended, (the "Arrangement Agreement") and became effective on May 16, 2025, resulting in Ascendant becoming a wholly owned subsidiary of Cerrado.» Mehr auf accessnewswire.com
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Ascendis Pharma ADR einen Umsatz von 100,95 Mio€ und ein Nettoeinkommen von −94,63 Mio€

(EUR)	März 2025	YOY
Umsatz	+100,95 Mio	5,28%
Bruttoeinkommen	+83,44 Mio	5,53%
Nettoeinkommen	−94,63 Mio	27,79%
EBITDA	−48,78 Mio	4,03%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+8,50 Mrd€
Anzahl Aktien	60,37 Mio
52 Wochen-Hoch/Tief	+160,95€ - +97,70€
Dividenden	Nein
Beta	0,4
KGV (PE Ratio)	−24,84
KGWV (PEG Ratio)	−2,26
KBV (PB Ratio)	−44,72
KUV (PS Ratio)	+23,16

Unternehmensprofil

Ascendis Pharma A/S, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung von Therapeutika für ungedeckte medizinische Bedürfnisse. Das Unternehmen bietet SKYTROFA für die Behandlung von Patienten mit Wachstumshormonmangel (GHD) an. Außerdem entwickelt es TransCon Growth Hormone (hGH) für pädiatrische GHD in Japan, TransCon hGH für Erwachsene mit GHD, TransCon Parathyroid Hormon für Hypoparathyreoidismus bei Erwachsenen und TransCon CNP für pädiatrische Achondroplasie. Darüber hinaus entwickelt das Unternehmen TransCon Toll Like Receptors 7/8 Agonist für die intratumorale Verabreichung und TransCon IL-2 ß/g für die systemische Verabreichung. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Hellerup, Dänemark.